Aura Biosciences Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Aura Biosciences Inc 's ROA in the second quarter of 2026?
Aura Biosciences Inc recorded a cumulative net loss of $-131 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -61.71%.

However, within the Healthcare sector 626 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 4067, from total ROA ranking in the first quarter of 2026 at 4690.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	71.5 %	-10.91 %	2.16 %	0.24 %	1.34 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-131	-112	-106	-106	-101
Return On Assets (TTM)	-61.71 %	-63.94 %	-58.99 %	-59.44 %	-56.64 %
AURA's Total Ranking	# 4067	# 4690	# 4111	# 4118	# 4152
Total Assets (TTM) in million	351	138	170	190	204
Seq. Total Assets Change	153.2 %	-18.66 %	-10.43 %	-7.03 %	31.53 %
Seq. Net Income Change	-	-	-	-	-

AURA's 5 Years Annual ROA >> Back to AURA Management Effectiveness >> Compare AURA ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 87
Sector	# 627
Overall	# 4014

Return On Assets Statistics
High	Average	Low
-35.16 %	-43.68 %	-64.08 %
(Jun 30 2022)		(Mar 31 2026)

News about Aura Biosciences Inc Return on Assets ROA

Aura Biosciences to Showcase Early-Stage Data in Non-Muscle Invasive Bladder Cancer and Welcomes New Leadership in Ur...

In an exciting development for the urologic oncology community, Aura Biosciences has announced its plans to host a pivotal investor event on October 17, 2024, where the company will present early data from its ongoing Phase 1 clinical trial focused on non-muscle invasive bladder cancer (NMIBC). This presentation is poised to shed light on the promising advancements in treatment options for one of the most prevalent forms of bladder cancer, and underline Aura’s commitment to innovation in this therapeutic landscape.Bladder cancer remains a significant public health challenge, with NMIBC accounting for approximately 70% of newly diagnosed cases. Current treatment strategies often fall short, highlighting the urgent need for novel therapies that can improve outcomes for patients who are facing this aggressive disease. Aura Biosciences is at the forefront of addressing this challenge with its innovative therapies, which leverage the power of viral-based technology.

Financial Statements
Aura Biosciences Inc 's Assets	$ 351 million	AURA's Balance sheet
Aura Biosciences Inc 's Income	$ -46 million	Quarterly AURA's Income Statement
AURA's Income by Division		See AURA's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	2.16 %	-30.21 %	16.54 %	28.77 %	-
Total Assets in million	170	167	239	205	159
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-106	-87	-76	-59	-35
Annual Return On Assets	-62.39 %	-52.17 %	-32.01 %	-28.69 %	-22.16 %

AURA's 5 Years Annual ROA >> Back to AURA Management Effectiveness >> Compare AURA ROA to its Competitors

More Return On Assets Ratios
AURA's' Return on Assets at Yahoo Finance
Biotechnology & Pharmaceuticals Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
AURA's Roa Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for AURA's Competitors
Subscribers only: Roa for Aura Biosciences Inc 's Suppliers
Subscribers only: Return On Assets for AURA's Customers

You may also want to know
AURA's Roi	AURA's Inventory Turnover Ratio	AURA's Growth Rates	AURA's Dividend Comparisons
	AURA's Profitability Ratios	AURA's Asset Turnover Ratio	AURA's Dividend Growth
AURA's Roe	AURA's Valuation Ratios	AURA's Financial Strength Ratios	AURA's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector

ROA

Date modified: 2026-09-05T14:56:22+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.